No connection

Search Results

ABBV vs MESO

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
MESO
Mesoblast Limited
BEARISH
Price
$14.70
Market Cap
$1.92B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ABBV
163.63
MESO
--
Forward P/E
ABBV
15.42
MESO
-210.0
P/B Ratio
ABBV
-146.66
MESO
32.96
P/S Ratio
ABBV
6.5
MESO
29.42
EV/EBITDA
ABBV
15.27
MESO
-294.48

Profitability

Gross Margin
ABBV
71.46%
MESO
-35.53%
Operating Margin
ABBV
35.5%
MESO
-55.16%
Profit Margin
ABBV
4.0%
MESO
-144.33%
ROE
ABBV
137.96%
MESO
-18.22%
ROA
ABBV
9.59%
MESO
-6.16%

Growth

Revenue Growth
ABBV
9.1%
MESO
1526.8%
Earnings Growth
ABBV
-88.7%
MESO
--

Financial Health

Debt/Equity
ABBV
--
MESO
0.24
Current Ratio
ABBV
0.72
MESO
1.58
Quick Ratio
ABBV
0.47
MESO
1.35

Dividends

Dividend Yield
ABBV
3.05%
MESO
--
Payout Ratio
ABBV
490.15%
MESO
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
MESO BEARISH

MESO presents a high-risk profile characterized by a stable but mediocre Piotroski F-Score of 4/9 and a complete absence of deterministic value markers like the Graham Number. While revenue growth is explosive (1526.8%), the company suffers from a catastrophic negative gross margin of -35.53%, meaning it loses money on its core product delivery. The valuation is extreme, with a Price-to-Book ratio of 32.96 and a Price-to-Sales ratio of 29.42, indicating the stock is priced for perfection despite consistent quarterly losses over several years.

Strengths
Explosive year-over-year revenue growth of 1526.80%
Low Debt-to-Equity ratio (0.24) indicating minimal leverage
Healthy short-term liquidity with a Current Ratio of 1.58
Risks
Negative Gross Margin (-35.53%) indicates a fundamentally flawed cost structure
Extreme valuation multiples (P/B 32.96, P/S 29.42) far exceeding industry norms
Chronic lack of profitability with negative earnings across 25 consecutive quarters

Compare Another Pair

ABBV vs MESO: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Mesoblast Limited (MESO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile